Arca
Skip to content
Tools
Tools

Cholestasis

Drug research and approvals for cholestasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 58 studies of cholestasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 4 approved and 4 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 58
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 4
  • EU medicines: 3

Recruiting now

Newest posted first, of 58 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 4

Phase 2 3

Phase 1 or earlier 1

How its trials ended

230 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 47 whose ending is known, 36% met their primary endpoint, 4% missed it and 60% stopped early.

  • Completed, result not reported7934%
  • Ongoing5725%
  • Status unknown4720%
  • Stopped: other or unclear198%
  • Met its primary endpoint177%
  • Stopped: enrollment or feasibility73%
  • Missed its primary endpoint21%
  • Stopped: safety1<1%
  • Stopped: funding1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Feb 14, 2020A long-term safety study of maralixibat, an apical sodium dependent bile acid transporter inhibitor (ASBTI), in the treatment of cholestatic liver disease in…Maralixibat (LUM001, SHP625)Mirum PharmaceuticalsClosed
Jan 2, 2020An open-label extension study to evaluate the long-term safety and efficacy of maralixibat in the treatment of subjects with progressive familial intrahepatic…MaralixibatMirum PharmaceuticalsClosed
Aug 22, 2019Randomized double-blind placebo-controlled phase 3 study to evaluate the efficacy and safety of maralixibat in the treatment of subjects with progressive…MaralixibatMirum PharmaceuticalsClosed
Sep 7, 2018An open-label extension study to evaluate long-term efficacy and safety of A4250 in children with progressive familial intrahepatic cholestasis types 1 and 2…Odevixibat (A4250)Albireo PharmaClosed
Mar 21, 2018A double-blind, randomized, placebo-controlled, phase 3 study to demonstrate efficacy and safety of A4250 in children with progressive familial intrahepatic…A4250Albireo PharmaClosed
Feb 6, 2014Open label study of the efficacy and long term safety of LUM001, an apical sodium-dependent bile acid transporter inhibitor (ASBTI), in the treatment of…Maralixibat (LUM001)Lumena Pharmaceuticals IncClosed

FDA orphan designations

Approved first, then open designations, newest first
Jul 24, 2024LivmarliTreatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC)Mirum Pharmaceuticals, Inc.Approved
Mar 13, 2024LivmarliTreatment of cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC)Mirum Pharmaceuticals, Inc.Approved
Jul 20, 2021BylvayTreatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use:…Ipsen Biopharmaceuticals, Inc.Approved
Jul 27, 2018OmegavenOmegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC)Fresenius Kabi USA, LLCApproved
Nov 18, 2024Modified human ATP binding cassette subfamily B member 4…Treatment of progressive familial intrahepatic cholestasis type 3 (PFIC3)Shenzhen Shenxin Biotechnology Co., Ltd.Designated
Jul 29, 2024Modified human ATP binding cassette subfamily B member 11…Treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)Shenzhen Shenxin Biotechnology Co., Ltd.Designated
Oct 22, 20203alpha,6beta,7beta,12alpha-tetrahydroxy-5beta-cholan-24-oic…Treatment of progressive familial intrahepatic cholestasisQing Bile Therapeutics, Inc.Designated
Feb 10, 1994Choline chlorideTreatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term…Protara Therapeutics, Inc.Designated

Medicines authorised in the EU

Newest first
Dec 9, 2022LivmarliMaralixibat chloride · orphanMirum Pharmaceuticals International B.V.EMA ↗
Jul 16, 2021BylvayOdevixibat · orphanIpsen PharmaEMA ↗
Jul 23, 2009VedropTocofersolanRecordati Rare DiseasesEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.